- Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer’s Disease
- The therapeutic potential of the endocannabinoid system for Alzheimer’s disease
- Endocannabinoid signalling in Alzheimer’s disease
- A molecular link between the active component of marijuana and Alzheimer’s disease pathology
- Neuroprotective effect of CBD… on beta-amyloid-induced toxicity in PC12 cells
- The Potential Therapeutic Effects of THC on Alzheimer’s Disease
- The Role of Endocannabinoid Signaling in the Molecular Mechanisms of Neurodegeneration in Alzheimer’s Disease
- Cannabinoids for the treatment of dementia
- CBD in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression
- CBD: A promising drug for neurodegenerative disorders?
- Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer’s disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition
- The role of the endocannabinoid system in Alzheimer’s disease
- The role of phytochemicals in the treatment and prevention of dementia
- Cannabinoids for the treatment of dementia
- Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression in SHSY5YAPP+ Cells Through PPARγ Involvement
- Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic
- Can Marijuana Prevent Alzheimer’s?
- Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia
- Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer’s Disease
- Natural Phytochemicals in the Treatment and Prevention of Dementia: An Overview
- Delineating the Efficacy of a Cannabis-Based Medicine at Advanced Stages of Dementia in a Murine Model
- CBD Modulates the Expression of Alzheimer’s Disease-Related Genes in Mesenchymal Stem Cells